Pharmacally
Disease & Drugs
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Disease & Drugs
Clinical TrialsVasa Reports NT-proBNP Reduction With VS-041 in HFpEF TrialVasa Therapeutics reports positive Phase 1c results for VS-041, with reduced NT-proBNP after 28 days in patients with HFpEF.Fact-Checked
Clinical TrialsBeeline Reports Positive Phase 2 Results for Afimetoran in SLEBeeline Medicines reported positive Phase 2 results for afimetoran in systemic lupus erythematosus, with all three doses meeting the primary endpoint.Fact-Checked
Clinical TrialsRegeneron’s CIDEB siRNA Sustains 80% Liver Fat ReductionRegeneron’s investigational CIDEBsiRNA reduced liver fat by up to 80% through week 36 following a single dose in adults with MASLD.Fact-Checked
Clinical TrialsAmgen’s Dazodalibep Meets Phase 3 Goal in Sjögren’s DiseaseAmgen’s dazodalibep met the primary endpoint in the Phase 3 OASIZ-301 trial, with both dosing regimens reducing systemic disease activity at Week 48.Fact-Checked
New Drug ApprovalAbbisko’s PIMJETMI Wins FDA Approval After 56% Response in TGCTAbbisko Therapeutics’ pimicotinib (PIMJETMI), an oral CSF-1R inhibitor, has received FDA approval for adults with symptomatic tenosynovial giant cell tumor (TGCT).Fact-Checked
Clinical TrialsNovartis Reports Two-Year Ianalumab Results in Sjögren’s DiseaseNovartis presented Week 108 findings from the NEPTUNUS extension study, showing further reductions in systemic disease activity with monthly ianalumab in patients with Sjögren’s disease.Fact-Checked
Clinical TrialsBeam Reports Positive BEACON Results for Risto-cel in SCDBeam Therapeutics’ investigational base-editing therapy risto-cel met the primary efficacy endpoint and all secondary efficacy endpoints in the BEACON Phase 1/2 trial, demonstrating 12-month freedom from severe vaso-occlusive…Fact-Checked
Drugs Safety AlertFDA Requires Class-Wide NAION Warning for GLP-1 DrugsThe FDA is requiring class-wide NAION labeling updates for GLP-1 receptor agonists after reviewing 126 randomized trials involving 134,253 patients.Fact-Checked
New Drug ApprovalBayer’s SUNHARBO Wins FDA Approval as First Factor XIa InhibitorBayer secures FDA approval for SUNHARBO (asundexian) 50 mg, the first Factor XIa inhibitor for secondary stroke prevention.Fact-Checked
Clinical TrialsAlnylam Highlights 5-Year Cardiovascular Benefits of VutrisiranAlnylam’s five-year HELIOS-B findings demonstrate sustained cardiovascular benefits with early and continuous vutrisiran treatment in patients with ATTR-CM, including lower mortality and recurrent cardiovascular event risks, better-preserved quality…Fact-Checked
Clinical TrialsMerck Reports Positive Phase 2b Results for Efinopegdutide in MASHMerck’s investigational GLP-1/glucagon receptor co-agonist efinopegdutide achieved its primary endpoint in a Phase 2b MASH trial, with 63% resolution at the 7 mg dose versus 13% with placebo.…Fact-Checked
Clinical TrialsBoehringer Reports Positive Phase III CV Safety Results for SurvodutideBoehringer Ingelheim’s survodutide met the primary cardiovascular safety endpoint in the Phase III SYNCHRONIZE-CVOT trial involving 5,530 adults with overweight or obesity and elevated cardiovascular risk.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.